Meloxicam Tillomed Laboratories (Meloxicam)

Meloxicam blocks the activity of cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. By lowering prostaglandin levels, the drug diminishes inflammation, pain signaling, and fever responses while preserving some COX‑1 activity to reduce gastrointestinal side effects compared with non‑selective NSAIDs.

The appropriate dose of meloxicam is determined by the prescribing clinician based on the patient’s specific condition, severity, age, renal and hepatic function, and concomitant medications. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without altering the regimen on their own.

The safety of meloxicam in pregnancy and lactation has not been definitively established. It is generally avoided during the first trimester and throughout pregnancy unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider, as meloxicam may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Meloxicam offers relatively selective COX‑2 inhibition compared with non‑selective NSAIDs, which may translate into a lower incidence of gastrointestinal irritation while still providing effective anti‑inflammatory and analgesic action. However, cardiovascular and renal risks remain similar to other NSAIDs, and choice of therapy should consider individual patient risk profiles.

Meloxicam should be stored at temperatures below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Meloxicam is taken orally, usually with a full glass of water. It can be taken with or without food, but patients who experience stomach upset may benefit from taking it with meals. The tablet should be swallowed whole and not crushed or chewed.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, severe skin reactions (e.g., Stevens‑Johnson syndrome), liver injury, and renal impairment. Patients should be monitored for signs of these conditions, and therapy should be discontinued if severe adverse events occur.

Meloxicam is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients who have had a recent coronary artery bypass graft. Caution is also advised for patients with compromised renal or hepatic function.